InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,964.89
(
0.28%
)
Post# of 251791
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mr_o

Send PM Follow Ignore
Followers 10
Posts 354
Boards Moderated 0
Alias Born 07/03/2013

mr_o

Re: biomaven0 post# 197743

Saturday, 11/28/2015 2:54:55 PM

Saturday, November 28, 2015 2:54:55 PM

Post# of 251791
Celgene's Revlimid ongoing patent litigation may become an example of this. Without looking it up, I think the first patents expire in 2018 with poly-morph patents extending until 2028. However, not sure if poly-morph patents fall under the formulation umbrella. And of course, it remains to be seen if the 2028 group of patents holds up in a court of law.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up